texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Fort Worth Cancer Center Research and Clinical Trials

The Fort Worth Cancer Center participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Fort Worth Cancer Center

Biliary Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Bladder Cancer

STAR INCB054828 Urothelial FGF/FGFR

A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations Read More

Phase: II

STAR INCB054828 Urothelial FGF/FGFR

A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations Read More

Phase: II

STAR Ph2 enfortumab (ASG-22CE)Urothelial

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More

Phase: II

Brain Cancer

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

Ph1/2 Roval Tesirine Solid Tumor

SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors Read More

Phase: I/II

Breast Cancer

Ph3 Abemaciclib HR+ HER2- (monarchE)

(I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer Read More

Phase: III

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

Non-Interv study Palbo HR+/HER2 AdvBC

POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082) Read More

Cervical Cancer

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Colon Cancer

Ph1 TSR-022 Adv Solid Tumors

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001) Read More

Phase: I

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

Ph 2/3 Nivo 1L mCRC

An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8) Read More

Phase: II/III

Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC

CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) Read More

Phase: III

Endometrial Cancer

PhIb/2 Lenvatinib (E7080)+Pembro Solids

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) Read More

Phase: I/II

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Esophageal Cancer

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

Fallopian Tube Cancer

PacCarboBev +/-Atezo, 1L Ovrn IMagyn050

A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523 Read More

Phase: III

Ph3 Nivo+Rucap Ovarian (ATHENA)

Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) Read More

Phase: III

Gastric Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Head and Neck Cancer

PhIb/2 Lenvatinib (E7080)+Pembro Solids

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) Read More

Phase: I/II

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Hematologic

Molecular Markers - Malignant Tumors

The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) Read More

Phase: IV

Liver Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

Lung Cancer

PhIb/2 Lenvatinib (E7080)+Pembro Solids

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) Read More

Phase: I/II

Ph1 TSR-022 Adv Solid Tumors

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001) Read More

Phase: I

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

STAR Ph2 Poziotinib EGFR/HER2 NSCLC

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202) Read More

Phase: II

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

Ph3 Adj canakinumab NSCLC

A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301) Read More

Phase: III

STAR Ph2 Brigatinib ALK+ NSCLC

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002) Read More

Phase: II

Ph2 Combo Therapies IO NSCLC-FRACTION

CA018-001/CA018-001A: Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung) Read More

Phase: II

Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC

CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer Read More

Phase: III/IV

Ph 1a/1b Rovalpituzumab Extensive SCLC

SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Extensive Stage Small Cell Lung Cancer Read More

Phase: I/II

Lymphomas

STAR Ph1/2 Tazemetostat r/r DLBCL & FL

An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101 Read More

Phase: I/II

STAR Brentux in older pts w/HL 1L

SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above Read More

Phase: II

Melanoma

PhIb/2 Lenvatinib (E7080)+Pembro Solids

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) Read More

Phase: I/II

Ph1 TSR-022 Adv Solid Tumors

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001) Read More

Phase: I

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

STAR Ph2 Pembro Recurr/Meta Cut. SCC

A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) Read More

Phase: II

Ph1/2 Roval Tesirine Solid Tumor

SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors Read More

Phase: I/II

Mesothelioma

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Myelofibrosis

STAR Ph2 Itacitinib +/- Ruxo in MF

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Read More

Phase: II

Neuroendocrine Tumors

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Ph1/2 Roval Tesirine Solid Tumor

SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors Read More

Phase: I/II

Ovarian Cancer

Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian

A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002) Read More

Phase: I/II

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

PacCarboBev +/-Atezo, 1L Ovrn IMagyn050

A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523 Read More

Phase: III

Ph3 Avelumab Ovarian JAVELIN 100 PARP

A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP 100)(B9991030) Read More

Phase: III

Ph3 Nivo+Rucap Ovarian (ATHENA)

Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) Read More

Phase: III

Pancreatic Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

Ph1/2 Roval Tesirine Solid Tumor

SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors Read More

Phase: I/II

Penile Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Peritoneal Cancer

PacCarboBev +/-Atezo, 1L Ovrn IMagyn050

A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523 Read More

Phase: III

Ph3 Nivo+Rucap Ovarian (ATHENA)

Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) Read More

Phase: III

Prostate Cancer

Ph1/2 Roval Tesirine Solid Tumor

SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors Read More

Phase: I/II

STAR Ph2 Rucaparib mCRPC (TRITON 2)

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052 Read More

Phase: II

STAR Rucaparib v PhysC mCRPC (TRITON3)

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More

Phase: III

Rectal Cancer

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

Ph 2/3 Nivo 1L mCRC

An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8) Read More

Phase: II/III

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC

CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) Read More

Phase: III

Renal Cancer

PhIb/2 Lenvatinib (E7080)+Pembro Solids

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) Read More

Phase: I/II

Lenvat+ever/pemb vs sunit 1L RCC [CLEAR]

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR) Read More

Phase: III

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Skin Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

STAR Ph2 Pembro Recurr/Meta Cut. SCC

A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) Read More

Phase: II

Solid Tumors

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Ph1 MSB0011359C Solid Tumors

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More

Phase: I

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Ph1/2 Roval Tesirine Solid Tumor

SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors Read More

Phase: I/II

Molecular Markers - Malignant Tumors

The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) Read More

Phase: IV

Testicular Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Thymomas

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Thyroid Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Ph1/2 Roval Tesirine Solid Tumor

SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors Read More

Phase: I/II

Urothelial Cancer

PhIb/2 Lenvatinib (E7080)+Pembro Solids

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) Read More

Phase: I/II

STAR INCB054828 Urothelial FGF/FGFR

A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations Read More

Phase: II

STAR INCB054828 Urothelial FGF/FGFR

A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations Read More

Phase: II

STAR Ph2 enfortumab (ASG-22CE)Urothelial

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More

Phase: II

Uterine Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II

Vaginal Cancer

Nivo in Advanced/Met Malignancies

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) Read More

Phase: II